Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CGAS | Q8N884 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 8/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26913323 | 0.87 | CGAS (0.44) | CGASROCK2ROCK1 | |
| SCHEMBL26912243 | 0.86 | CGAS (0.39) | CGASROCK2ROCK1BTK | |
| SCHEMBL26913748 | 0.83 | USP2 (0.43) | CGASROCK2ROCK1 | |
| SCHEMBL26912433 | 0.83 | ROCK2 (0.40) | CGASROCK2ROCK1 | |
| SCHEMBL26912685 | 0.82 | CGAS (0.35) | CGASROCK2ROCK1 | |
| SCHEMBL26913242 | 0.80 | CGAS (0.38) | CGASROCK2ROCK1 | |
| SCHEMBL26912644 | 0.80 | CGAS (0.40) | CGASROCK2ROCK1 | |
| SCHEMBL26913349 | 0.79 | CGAS (0.41) | CGASROCK2ROCK1 | |
| SCHEMBL26912510 | 0.78 | CGAS (0.35) | CGASROCK2ROCK1 | |
| SCHEMBL26912763 | 0.78 | CGAS (0.39) | CGASROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | CGAS 1/4885ABL1 415/4885EGFR 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.